Mirvetuximab Soravtansine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Mirvetuximab Soravtansine. Educational only — not medical advice.
Labeled uses
ELAHERE® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )].
Source: FDA labeling via NIH DailyMed (set 00c424b5…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.